1. Melanom – Endlich gute Neuigkeiten.
- Author
-
Wicki, Andreas, Arnold, Andreas W., Itin, Peter H., and Zippelius, Alfred
- Subjects
- *
MELANOMA treatment , *IPILIMUMAB , *SYSTEMIC family therapy , *CYTOTOXIC T cells , *IMMUNE response , *DISEASE remission ,TUMOR prognosis - Abstract
Until two years ago, there was no systemic therapy that prolonged overall survival in patients with malignant melanoma. In the meantime, two new therapeutic approaches have improved the prognosis of this disease. Ipilimumab is an activator of cytotoxic Tcells. It induces an immune response which results in prolonged remission in 15-20% of patients. Vemurafenib is a specific BRAF inhibitor and induces quick and sometimes complete remissions in patients with BRAF V600E mutated melanomas. Thus, there are two new treatments with proven survival benefit in patients with metastatic melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF